Genset, Pharmacia and Upjohn Sign Two-Year Collaboration Deal

PARIS--Genset, a genomics company here, struck a two-year research agreement with Pharmacia and Upjohn in which the companies will use Genset's pharmacogenomics technology to identify genetic markers among patients involved in clinical studies of a Pharmacia and Upjohn compound. Using a proprietary high-resolution biallelic marker map, Genset said it will analyze well characterized data and samples of responders and nonresponders from selected Pharmacia and Upjohn clinical studies to maximize the practical medical and pharmaceutical applications of its genomics discoveries. Genset will receive research fees, research and clinical milestone payments, and royalty payments on future sales of the collaborative compound that would make use of the pharmacogenomics discoveries.